UCB S.A.
OTC: UCBJY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jean-Christophe Tellier
- Employees
- 9,052
- Headquarters
- Brussels, Belgium
- IPO year
- 2012
- Market cap
- $54.5B
- Website
- https://www.ucb.com
Loading UCBJY…
Loading profile data…Frequently asked questions about UCBJY
What does UCB S.A. (UCBJY) do?
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-r...
Where does UCBJY trade?
UCB S.A. (UCBJY) trades on the Other OTC.
What sector is UCBJY in?
UCB S.A. (UCBJY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of UCB S.A.?
Jean-Christophe Tellier is the chief executive officer of UCB S.A. (UCBJY).
Where is UCB S.A. headquartered?
UCB S.A. is headquartered in Belgium.
Does UCBJY pay a dividend?
Yes — UCB S.A. (UCBJY) paid a trailing twelve-month dividend of USD 0.85 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did UCBJY go public?
UCB S.A. (UCBJY) completed its initial public offering in 2012.
Is UCBJY an ADR?
Yes — UCBJY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. UCB S.A. reporting and dividends follow the underlying issuer.